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Abstract
Purpose This systematic review aims to summarize the cur-
rent literature regarding potential effects of having both cancer
and diabetes on patient-reported outcomes (PROs) and to pro-
vide directions for future research.
Methods MEDLINE, The Cochrane Library, CINAHL, and
PsycINFO were searched from inception to January 2015. All
English peer-reviewed studies that included patients with both
cancer and diabetes and assessed PROs were included. All
included studies were independently assessed onmethodolog-
ical quality by two investigators.
Results Of the 3553 identified studies, 10 studies were includ-
ed and all were considered of high (40 %) or adequate (60 %)
methodological quality. Eight of the 10 studies focused on
health-related quality of life (HRQoL), functioning, or symp-
toms and 2 studies assessed diabetes self-management. Over-
all, HRQoL and functioning was lower, and symptoms were
higher among patients with both cancer and diabetes as com-
pared to having cancer or diabetes alone. Furthermore, one
study reported that diabetes self-management was impaired
after chemotherapy.
Conclusions Having both cancer and diabetes resulted in
worse PROs compared to having either one of the diseases,
however, the considerable heterogeneity of the included stud-
ies hampered strong conclusions. Future studies are needed as
this research area is largely neglected. As the majority of the
included studies focused on HRQoL, future research should
address the impact of both diseases on other PROs such as
depression, patient empowerment and self-management.
Implications for Cancer Survivor Having both cancer and
diabetes might result in worse PROs, however, more research
is needed as current evidence is scarce.
Keywords Cancer . Diabetes . Patient-reported outcomes .
Systematic review . Health-related quality of life
Introduction
Due to the increased aging of the population, early detection,
and better treatment of diseases, the number of cancer survi-
vors is increasing [1]. As a result, more and more cancer
survivors live with other chronic diseases of which diabetes
is one of the most prevalent [2]. The prevalence of concurrent
diabetes among cancer patients depends on cancer type, gen-
der, and age at diagnosis and varies from 8 % among prostate
cancer patients to approximately 26% among pancreas cancer
patients aged 65 years or older [2]. This high prevalence of
diabetes among cancer patients results in worse outcomes and
increases the burden on health systems worldwide.
The link between cancer and diabetes is extensively studied
in recent literature and is mainly focused on the impact of
diabetes on cancer incidence and mortality. Recent meta-
analyses show that diabetes is strongly associated with the
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development of pancreatic (OR=1.82, 95 % CI: 1.66–1.89)
[3], liver (OR=2.50, 95%CI: 1.80–3.50) [4], and endometrial
cancer (RR=2.10, 95 % CI: 1.75–2.53) [5]. Moderate, posi-
tive associations have been reported for diabetes and breast
(RR=1.20, 95 % CI: 1.12–1.28) [6], colorectal (RR=1.26,
95 % CI: 1.05–1.50) [7], and bladder (RR=1.24, 95 % CI:
1.08–1.42) [8] cancer incidence, while diabetes has been as-
sociated with a decreased incidence of prostate cancer (RR=
0.84, 95 % CI: 0.76–0.93) [9]. Furthermore, previous research
shows that having diabetes is associated with a 30–40 % in-
creased mortality risk among cancer patients, which was
mainly apparent among breast, endometrial, and colorectal
cancer patients [10, 11].
As the group of patients with both cancer and diabetes is
growing, patients’ experience of living with both diseases is
becoming more important. However, this research area is
largely neglected. Patient-reported outcome (PRO) assess-
ments such as health-related quality of life (HRQoL), func-
tioning, and symptoms are needed as it is plausible that pa-
tients with multiple chronic diseases experience more prob-
lems. This knowledge is essential to improve clinical practice
and care for this growing group of patients.
A significant number of cancer survivors consistently re-
port lower physical functioning, sexual functioning, and more
symptoms of distress and fatigue [12, 13]. Similarly, diabetes
patients are more likely to suffer from depression [14], report a
lower quality of life [15], and lower sexual functioning [16].
As both cancer and diabetes patients report deteriorated PROs
compared to people without the disease, we hypothesize that
having both chronic diseases will result in even more deterio-
rated PROs. The aim of this systematic literature review is to
summarize the current knowledge on the impact of having
both cancer and diabetes on PROs. In addition, as we expect
that this research area will be largely neglected, we also aim to
provide directions for future research.
Methods
Search strategy
LF conducted the systematic literature search on August 2013
and updated the search on January 2015. The following data-
bases were included: MEDLINE, The Cochrane Library,
CINAHL, and PsycINFO. Subject headings and freetext terms
for diabetes (i.e., diabet* OR diabetes mellitus) were com-
bined with search terms for cancer (i.e., cancer* OR neo-
plasm* OR oncolog*). As PROs cover a wide range of differ-
ent aspects, we did not include any search terms for PROs to
avoid missing relevant papers. The full search strategy is
shown in Online Resource 1. After the search was conducted,
the cited references of the selected studies were searched using
Web of Science and their references lists checked; in addition,
PubMed related articles were used for the two most recent
included studies to identify studies that were not found with
the initial literature search.
Selection criteria
All retrieved studies (including abstracts of unpublished stud-
ies) were screened and studies that met the following four
selection criteria were included: (1) the study is focused on
patients with both cancer and diabetes, (2) PRO is primary or
secondary outcome measure of the study, (3) is published in a
peer-reviewed journal, and (4) is published in English. Studies
that assessed the effects of several chronic or comorbid dis-
eases, including diabetes, among cancer patients on PROs
were not included as the studies should have a primary focus
on both cancer and diabetes. Similarly, studies that aimed to
address comorbid or chronic diseases, including cancer,
among diabetes patients were excluded.
Quality assessment
Each selected study was independently scored on methodo-
logical quality by 2 reviewers (PVand MT) based on a set of
14 quality criteria (Table 1). These quality criteria were based
on established criteria lists used in previous studies [17, 18].
Disagreements between the reviewers on the quality criteria
were resolved during a consensus meeting. All studies re-
ceived 1 point for each of the 14 quality criteria that was
met. If a criterion was not met or described insufficiently, 0
point was assigned. Thus, each study can obtain a maximum
score of 14 points. Studies that scored 75 % or more of the
maximum attainable score (i.e., ≥11 points) were considered
as Bhigh quality study,^ studies scoring between 50–75 %
(i.e., 7–10 points) were considered of Badequate quality,^
while those scoring <50 % (i.e., ≤6 points) were considered
of Blow quality.^ These criteria were arbitrarily chosen and
based on previous research [17].
Results
Description of the included studies
The initial broad search strategy on cancer and diabetes that
did not include a term for BPROs^ yielded 3553 hits, and after
the removal of duplicates and the application of selection
criteria, a total of 10 studies were included in this study, of
which 2 were based on the same data [19, 20] (Fig. 1). Eight of
the included studies had a sample size of at least 590 partici-
pants, while 2 studies, based on the same data, included 43
patients [19, 20] (Table 2). The number of patients with both
cancer and diabetes was rather low; 5 studies included less
than 100 patients with both diseases [19–23]. Moreover, only
J Cancer Surviv (2016) 10:406–415 407
4, of which 3 unique, studies had a longitudinal design [19,
20, 24, 25], while the other 6 studies addressed the associa-
tions between cancer and diabetes and PROs cross-sectionally
[21–23, 26–28]. Most studies focused on patients with specif-
ic cancer types including patients with diabetes and prostate
[22–25], colorectal [27, 28], or breast cancer [23]. Five studies
included cancer patients with diabetes (CA+DM+) and made
a comparison with cancer patients without diabetes (CA+
DM-) [21, 22, 24, 25, 28], one study compared CA+DM+
patients with patients with diabetes only (CA-DM+) [23]
and two studies included CA+DM-, CA-DM+ and patients
without both diseases (CA-DM-) for comparison [26, 27].
Two studies, based on the same data, only included CA+
DM+ and did not include a comparison group [19, 20]. Of
the 10 included studies, 8 focused on HRQoL, self-perceived
health status, functioning, or symptoms, while 2 studies
assessed the impact of cancer and its treatment on diabetes
self-management. Most studies used a validated question-
naire. The Short Form (SF)-36 was used most frequently to
assess HRQoL or self-perceived health status [21, 22, 25],
other studies used the Health Utility Index Mark 3 (HUI3)
[26], the EuroQoLGroup’s EQ-5D [23], the Audit of Diabetes
Dependent Quality of Life (ADDQoL) [23], the European
Organization for Research and Treatment of Cancer core
Quality of Life Questionnaire (EORTC QLQ-C30) [27], or
the University of California, Los Angeles, Prostate Cancer
Index (UCLA-PCI) [22, 24, 25]. The EORTC QLQ-
Chemotherapy-Induced Peripheral Neuropathy (CIPN)-20
was used to assess neuropathic symptoms [28]. Eight out of
10 studies conducted multivariate analyses and mainly adjust-
ed for socio-demographic [19, 21, 22, 24–28] and cancer-
related covariates [19, 21, 22, 25, 27, 28], while diabetes-
related covariates [19] and lifestyle factors [24, 26–28] were
less often adjusted for.
Study quality
The 10 included studies scored a mean quality score of 10 out
of 14, and scores ranged between 7 and 13. Four studies (40
%) were classified as being of high quality and 6 (60 %) of
adequate quality according to our quality criteria. No studies
were considered of low quality. The criteria that were least
often met are (#4) the inclusion of a (healthy) normative sam-
ple for comparison, (#7) a description of at least two clinical
variables regarding diabetes diagnosis, and (#10) information
is given regarding differences in demographic and/or clinical
characteristics of respondents vs non-respondents (all met by
3 studies) (Table 1).
Table 1 List of criteria for assessing the methodological quality of studies on patient-reported outcomes among patients with cancer and diabetes
Positive if with respect to Number of studies
that scored positive
Patient-reported outcomes N (%)
1. Examining PROs was a primary objective of the study 10 (100)
2. A validated questionnaire to measure PROs was used 10 (100)
Study population
3. The patient sampling process is described 10 (100)
4. A (healthy) normative sample is included for comparison 3 (30)
5. Patients with both cancer and diabetes are compared to either patients with only cancer or only diabetes on
at least two sociodemographic variables
8 (80)
6. A description is included of at least two clinical variables regarding cancer diagnosis
(e.g., cancer stage, treatment, time since cancer diagnosis)
8 (80)
7. A description is included of at least two clinical variables regarding diabetes diagnosis or severity
(e.g., HbA1c levels, treatment, time since diabetes diagnosis)
3 (30)
8. Inclusion and/or exclusion criteria are described 9 (90)
9. Participation rates for patient groups are described and these are >75 % 4 (40)
10. Information is given regarding differences in demographic and/or clinical characteristics of
respondents vs non-respondents
3 (30)
Study design
11. The study sample includes at least 75 patients (arbitrarily chosen) 8 (80)
12. The process of data collection is described 8 (80)
13. The difference in the outcome variable between cancer patients with diabetes and patients
with only cancer and/or only diabetes is assessed in multivariable models,
including at least 2 covariates
8 (80)
Results
14. Mean, median, standard deviations, or percentages are reported and compared between cancer patients with
diabetes and patients with only cancer and/or only diabetes for the most important outcome measures
8 (80)
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HRQoL, functioning, and symptoms
All included studies reported worse PROs among CA+DM+
compared to CA+DM-, CA-DM+, or CA-DM- on at least 1
studied item or subscale, except for 1 longitudinal study [25].
Nine out of the 10 included studies assessedmore than 1 PRO,
while 1 study only included a general measure of HRQoL
[26].
General HRQoL
A large cross-sectional study conducted in Canada reported
lowest average HRQoL scores for CA+DM+ (n=940)
followed by CA+DM- (n=1,692), CA-DM+ (n=4,394), and
CA-DM- (n=107,295) patients with average HUI3 scores
ranging between 0.67 and 0.89 (i.e., where −0.36=worst pos-
sible health, 0=death, and 1=perfect health) [26]. The HUI3
indirectly measures HRQoL using 8 attributes (vision, hear-
ing, speech, ambulation, dexterity, emotion, cognition, and
pain) and a mean difference of 0.03 was considered as clini-
cally important. Multivariable regression analyses showed
similar results with a lower HRQoL for CA+DM+, CA+
DM-, and CA-DM+ patients as compared to CA-DM- patients
with beta’s of −0.10, −0.04, and −0.04, respectively, which
was regarded clinically relevant [26]. Similarly, lower general
health was reported in a cross-sectional study among 65 pros-
tate cancer patients with vs 525 without diabetes with average
SF-36 scores of 51.9 vs 62.5, which remained significant in
multivariable analyses (beta=−0.13) [22]. A longitudinal
study among prostate cancer patients did observe differences
between CA+DM+ and CA+DM- in general health at base-
line, but after adjustments for age, marital status, educational
level, income, employment status, baseline HRQoL, cancer
stage, primary treatment, baseline PSA, and baseline Gleason
score, this difference did not remain significant [25]. Other
studies did not report a worse general health among those with
both cancer and diabetes [23, 27].
Physical functioning or mobility
Five studies included a measure of physical functioning or
mobility. In a study with 76 CA+DM+ and 585 CA+DM-,
CA+DM+ scored on average 12 points lower on the physical
functioning subscale of the SF-36 as compared to CA+DM-
[21], as this difference was larger than 0.5 times the standard
deviation it can be considered to be clinically relevant [29].
Similarly, a cross-sectional study found more problems with
mobility and usual activities among men with prostate CA+
*Selection criteria include: the study (1) includes patients with both cancer and diabetes, (2) PRO is 
primary or secondary outcome measure of the study, (3) is published in a peer-reviewed journal, and 
(4) is published in English 
** Article of our own research group was accepted for publication on the 13th of January 2015 and 
published online on 3 February 2015 
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DM+ as compared to CA-DM+, but this difference was not
found among women with breast cancer [23]. Colorectal CA+
DM+ reported a worse physical functioning as compared to
CA+DM- (beta=−3.8) [27]. Two studies did not report lower
physical functioning among CA+DM+ [22, 25], however,
one study did report lower vitality among prostate CA+
DM+ as compared to CA+DM- (beta=−0.12), which was
considered a clinically relevant difference [22].
Sexual functioning
Sexual functioning was assessed in one study among colorec-
tal CA+DM+ [27] and in two studies with prostate CA+DM+
[24, 25]. Colorectal CA+DM+ reported more male sexual
problems compared to colorectal CA+DM- (beta=9.4) in a
cross-sectional study from the Netherlands [27]. Among pros-
tate cancer patients, two longitudinal studies did not observe a
significant association between comorbid diabetes and sexual
functioning [24, 25].
Urinary and bowel functioning
Three studies among prostate cancer CA+DM+ and CA+DM-
patients also focused on prostate cancer-specific symptoms, in-
cluding urinary functioning and/or bowel functioning [22, 24,
25]. One study reported lower urinary function during follow-
up among prostate CA+DM+ as compared to CA+DM-
(mean score 72±24 vs 77±22) [24], but the other studies did
not report differences in urinary or bowel functioning [22, 25].
Neuropathic symptoms
A cross-sectional study by our research group among 218
colorectal CA+DM+ and an age- and sex-matched sample
of 975 CA+DM- patients assessed differences in neuropathic
symptoms. CA+DM+ patients reported more neuropathic
symptoms regardless of cancer treatment as compared with
CA+DM- patients regarding tingling fingers or hands (OR=
1.40; 95 % CI: 1.00–1.94), tingling toes or feet (OR=1.47
95 % CI: 1.04–2.07), numbness in toes or feet (OR=1.83;
95 % CI: 1.28–2.62), and erection problems among men
(OR=1.83; 95 % CI: 1.11–3.03) [28]. However, the majority
of reported symptoms were of mild severity.
Mental Health
CA+DM+ patients did not report worse mental health or emo-
tional functioning compared to CA+DM- or CA-DM+ in 3
cross-sectional [21, 22, 27] and 1 longitudinal study [25]. One
study included a measure of problems with anxiety, but no
significant differences were found between prostate or breast
CA+DM+ as compared to CA-DM+ patients in unadjusted
analyses [23].
Diabetes self-management
Two studies, using the same longitudinal data, addressed
problems with diabetes self-management among 43 patients
with a solid tumor and type 1 or 2 diabetes [19, 20]. One study
showed that patients reported higher scores on symptom bur-
den and lower scores on diabetes self-management after
8 weeks on chemotherapy as compared to baseline (mean
32.57±4.49 vs 25.43±3.81 and 45.86±2.65 vs 50.84±2.47,
respectively) [20]. In addition, a moderate impact of cancer on
diabetes self-management was observed, which mainly affect-
ed the ability to exercise, blood sugar monitoring, and ability
to eat and drink. Moreover, in qualitative assessments many
individuals indicated that they prioritized cancer care instead
of diabetes care [20]. The other study mainly focused on pre-
dictors of diabetes self-management [19]. This study showed
that living arrangements, years with DM, the total number of
medications, baseline DM self-management, DM self-effica-
cy, and baseline and 8-week symptom severity were signifi-
cant predictors of diabetes self-management, while diabetes
complications, cancer type, stage and treatment, outcome ex-
pectancies, and anxiety and depression were not [19].
Discussion
The majority of the included studies in this systematic review
(i.e., 8 out of 10 studies) addressed HRQoL, self-perceived
health, functioning or symptoms, and two studies, based on
the same data, assessed diabetes self-management. In all in-
cluded studies, CA+DM+ patients reported worse outcomes,
but in 1 longitudinal study among prostate cancer patients,
differences disappeared after adjustments [25]. CA+DM+ pa-
tients mainly scored lower on general HRQoL [22, 26], phys-
ical functioning [21, 23, 27], and sexual functioning [27]. In
addition, prostate CA+DM+ patients reported lower urinary
functioning [24] and lower vitality [22], while colorectal CA+
DM+ vs CA+DM- patients reported more neuropathic symp-
toms in a cross-sectional study [28]. Finally, among diabetes
patients that also had concurrent cancer, symptom severity
increased and diabetes self-management, mainly exercise,
blood sugar monitoring, and the ability to eat and drink, was
impaired after 8 weeks on chemotherapy [20].
Similar to the results found in our systematic review, liter-
ature shows that comorbidity has a significant impact on
HRQoL. Several other studies that were not included in this
review but included diabetes as one of the studied comorbid
conditions showed that cancer patients with comorbidity re-
ported lower HRQoL or functioning [30–33]. A few of those
studies reported the impact of diabetes separately and found a
poorer general health [30], lower physical functioning [30,
33], more symptoms of nausea [31], and more erection prob-
lems among CA+DM+ men [32]. In line with these results,
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the number of comorbidities, including cancer, among pa-
tients with diabetes has also been shown to result in poorer
HRQoL [34]. These studies were excluded from the present
review as CA+DM+ patients were not the main sample, and
as a result the number of included patients with both diseases
was often low.
Although the included studies were of adequate to high
quality, they differed substantially in design, population, and
methodology. Different instruments were used to measure
HRQoL which hampers comparison of the results. Moreover,
different cancer types were studied and sample sizes in sub-
groups were generally low, particularly for CA+DM+ pa-
tients. The majority of studies included CA+DM+ and CA+
DM- patients, although some studies additionally included a
normative sample or CA-DM+ patients for comparison. As a
result, information regarding diabetes characteristics was
scarce with only 3 out of 10 studies including clinical data
regarding diabetes. However, it is important to take the dura-
tion and severity of diabetes into account as this may influence
the outcomes. Only 4 prospective studies were included, of
which 2 were based on the same data, and these studies were
conducted mainly among prostate cancer patients.
Despite the heterogeneity in patient samples and PROs
studied, this systematic review also has several strengths. It is
the first to summarize the literature on PROs among CA+DM+
patients. In addition, a broad search strategy was used and
thereby a complete overview of the previous literature is pre-
sented. Finally, the quality of all included studies was assessed
by two independent investigators with a 14-item checklist.
Directions for future research
Although previous studies suggest that having both cancer
and diabetes results in worse outcomes, the evidence is scarce
and many relevant topics have not been studied yet. This
systematic review shows that the majority of studies focused
on general HRQoL and physical function, however, only little
attention has been paid to mental health. Mental health was
assessed in 5 of the 10 included studies but did not appear to
be deteriorated in CA+DM+ patients as compared with CA+
DM- and CA-DM+ patients. However, this might be a result
of the used instrument, as all studies used a subscale of a
HRQoL instrument, which might not be sensitive to more
specific symptoms of anxiety or depression. Depression is a
common problem in both cancer and diabetes patients. Previ-
ous research shows that depression is highly prevalent, in
about a third of all cancer as well as diabetes patients and is
associated with worse prognostic outcomes [35–38]. There-
fore, it is possible that CA+DM+ patients might encounter
more mental health issues, which were not picked up in the
limited studies in this review. Thus, future studies should fo-
cus on mental health issues, including depression among
CA+DM+ patients.
Previous studies show that among both cancer and diabetes
patients BMI, physical activity, and smoking are significant
predictors of HRQoL [39–43]. However, only 4 of the studies
included in this review adjusted for lifestyle factors of which 3
only included BMI [24, 27, 28] and 1 study additionally ad-
justed for physical activity and smoking [26]. These studies
showed that CA+DM+ patients have a higher BMI [24,
26–28] and are less physically active [26] at baseline than
those without diabetes. Although, these studies did observe
lower HRQoL among CA+DM+ vs CA+DM- patients inde-
pendent of the adjustment for lifestyle factors, more research
is needed. It is important to assess whether the poorer lifestyle,
rather than clinical factors, of CA+DM+ patients is responsi-
ble for the lower HRQoL in this group. Moreover, future re-
search should focus on the effect of changes in lifestyle factors
and their impact on HRQoL; with that knowledge, interven-
tions can be developed to improve HRQoL on the long term.
Elderly often live with several chronic illnesses such as
cancer and diabetes, which poses a burden on patients. Due
to the improved survival, self-management of these chronic
diseases is becoming more important. This review included
two studies on diabetes self-management which showed that
cancer patients performed fewer diabetes self-management
behaviors, such as monitoring of the blood glucose levels
and exercising, after 8 weeks on chemotherapy [20]. More-
over, qualitative research showed that diabetes patients who
develop cancer prioritize their cancer care over their diabetes
care [20]. Among diabetes patients, self-management is wide-
ly studied and a previous literature review and meta-analysis
shows that self-management interventions can improve blood
glucose levels, increase knowledge and self-efficacy, and
eventually might reduce costs of healthcare utilization [44].
It is important that both patients as well as specialists recog-
nize the importance of self-management of multiple chronic
illnesses. It is important that patients are able to utilize their
resources and feel that they are in control of life and solve
problems when necessary. Therefore, we believe that empow-
erment of patients and improving self-management behavior
are important topics to address in future studies among pa-
tients with multiple chronic diseases.
Conclusion
In conclusion, this systematic review indicates that having
both cancer and diabetes results in worse PROs. However, a
relatively low number of studies were included and no defin-
itive conclusions can be drawn because of the heterogeneity of
the included studies. The included studies were of reasonable
quality but a main issue was that clinical information regard-
ing diabetes was missing. More prospective studies with suf-
ficient sample sizes are needed to establish these findings. As
this research area is largely neglected and the majority of
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studies focused on HRQoL and physical function, future re-
search should focus on other PROs that are highly prevalent
among both cancer and diabetes patients such as mental
health, including depression. In addition, as the occurrence
of multiple chronic diseases poses important constraints on a
person’s life and their health care, topics such as self-care and
patient empowerment should receive more attention in future
research.
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